Basic Information
ID DDInter1347 and DDInter1102
Interaction Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lumateperone, which is metabolized by the isoenzyme in vitro.
Management Coadministration of CYP450 3A4 inducers with lumateperone should be avoided.
References [1] "Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc., New York, NY. [2] "Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc., New York, NY.
Alternative for Oritavancin J01X
Tinidazole Linezolid Bacitracin Polymyxin B Daptomycin Vancomycin
Metronidazole Telavancin Methenamine Spectinomycin Nitrofurantoin
More
Alternative for Lumateperone N05A
Fluphenazine Haloperidol Thiothixene Risperidone Amisulpride Quetiapine
Prochlorperazine Promazine Thioridazine Pimozide Trifluoperazine
More
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.